Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial) - 21/08/11
, Gert Bellen, RN a, Geert Byttebier, MSc c, Luc Verguts, MD d, Piet Hinoul, MD e, Ronald Walckiers, MD f, Michel Stalpaert, MSc g, Annie Vereecken, MPharm g, Johan Van Eldere, MD, PhD h
Reprints: Gilbert Donders, MD, PhD, Department of Obstetrics and Gynaecology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, BelgiumRésumé |
Objective |
Although many women with recurrent vulvovaginal candidiasis initially benefit from prophylactic intermittent treatment with antimycotics, most of them experience relapse after cessation of therapy, and often they return to the pretreatment recurrence rate. The purpose of this study was to demonstrate the efficacy and safety of an individualized, degressive, prophylactic regimen in 136 women with recurrent vulvovaginal candidiasis.
Study Design |
After an induction dose of 600 mg fluconazole during the first week, 117 women started maintenance therapy: 200 mg fluconazole weekly for 2 months, followed by 200 mg biweekly for 4 months, and 200 mg monthly for 6 months, according to their individual response to therapy. All women were tested for recurrences monthly with wet mount microscopy and vaginal culture during the first 6 months and bimonthly during the next 6 months. Patients were allowed to move on to the next level of maintenance therapy only if they were symptom free and microscopy and culture negative.
Results |
Of the women who were cured successfully after the induction phase, 101 women (90%) were disease-free after 6 months of maintenance therapy with this degressive regimen, and 80 women (77%) were disease-free after 1 year. The weekly incidence of the first clinical relapse was 0.5% during any period of the maintenance phase, and the rate of all new relapses, which included evidence of mycologic or microscopic colonization, was 1% per week. Women who experienced several relapses (poor responders) had experienced more relapses before entering the study compared with the optimal responders (odds ratio, 4.9; 95% CI,1.8-13.7; P = .002), experienced the disease for a longer period of time (6.5 vs 3.7 years; P = .06), and harbored significantly more Candida non-albicans during maintenance therapy (P = .001). No serious side-effects were noted.
Conclusion |
Individualized, degressive, prophylactic maintenance therapy with oral fluconazole is an efficient treatment regimen to prevent clinical relapses in women with recurrent vulvovaginal candidiasis.
Le texte complet de cet article est disponible en PDF.Key words : candidiasis, chronic disease, fluconazole, prophylactic treatment, vaginitis
Plan
| Cite this article as: Donders G, Bellen G, Byttebier G, et al. Individualized decreasing-dose maintenance fluconazole regimen for recurrent vulvovaginal candidiasis (ReCiDiF trial). Am J Obstet Gynecol 2008;199:613.e1-613.e9. |
|
| Femicare received an educational Grant from Pfizer in 2002-2005. |
Vol 199 - N° 6
P. null - décembre 2008 Retour au numéro
Article précédent
- Graphic integration of causal factors of pelvic floor disorders: an integrated life span model
- John O.L. DeLancey, Lisa Kane Low, Janis M. Miller, Divya A. Patel, Julie A. Tumbarello
- Continuing improvement of chronic pelvic pain in women after short-term Mensendieck somatocognitive therapy: results of a 1-year follow-up study
- Gro K. Haugstad, Tor S. Haugstad, Unni M. Kirste, Siv Leganger, Slawomir Wojniusz, Inger Klemmetsen, Ulrik F. Malt
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?